SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-005038
Filing Date
2022-01-10
Accepted
2022-01-10 07:07:32
Documents
14
Period of Report
2022-01-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d157429d8k.htm   iXBRL 8-K 32857
2 EX-99.1 d157429dex991.htm EX-99.1 26282
6 GRAPHIC g157429g0108093142010.jpg GRAPHIC 2838
  Complete submission text file 0001193125-22-005038.txt   197034

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fulc-20220105.xsd EX-101.SCH 2894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fulc-20220105_lab.xml EX-101.LAB 18122
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fulc-20220105_pre.xml EX-101.PRE 11406
8 EXTRACTED XBRL INSTANCE DOCUMENT d157429d8k_htm.xml XML 3356
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 22519657
SIC: 2834 Pharmaceutical Preparations